In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Lineage Therap, with a price target of $9.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Joseph Pantginis has given his Buy rating due to a combination of factors including Lineage Cell Therapeutics’ strong financial position and promising clinical data. The company reported a cash balance of $42.3 million, which is expected to sustain operations into the first quarter of 2027, providing a solid financial runway for ongoing and future projects.
Additionally, the OpRegen program, in collaboration with Roche/Genentech, has shown significant differentiation in treating geographic atrophy in dry-AMD patients, with impressive three-year follow-up data. The company’s innovative GMP manufacturing platform further enhances its potential by enabling scalable and cost-effective production across multiple programs, positioning Lineage for substantial growth in the cell therapy market.
In another report released on August 6, Maxim Group also maintained a Buy rating on the stock with a $3.00 price target.